New Gene-Modified immune cells take on tough lymphoma
NCT ID NCT06378190
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment called TranspoCART19 for people with B-cell lymphoma that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, which are genetically modified to better recognize and attack cancer cells. The trial will enroll 27 adults and aims to find the safest dose and measure how well the therapy works over 36 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CAR-T cells (genetically modified immune cells targeting CD19)
- What this could lead to
- If successful, this could offer a new treatment option for people with hard-to-treat B-cell lymphoma.
- What could go wrong
- This is an early-phase trial with only 27 participants, so results may not apply to everyone. There are risks of serious side effects from the therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA RECURRENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clínica Universidad de Navarra
RECRUITINGPamplona, Navarre, 31008, Spain
-
Fundación Jiménez Díaz Hospital
RECRUITINGMadrid, Madrid, Spain
-
Hospital Clínic
NOT_YET_RECRUITINGBarcelona, Barcelona, Spain
-
Institut Català d'Oncologia Hospital
RECRUITINGL'Hospitalet de Llobregat, Barcelona, Spain
-
Salamanca University Health Care Complex
RECRUITINGSalamanca, SALAMANCA, 37007, Spain
-
University Hospital of Navarra
RECRUITINGPamplona, Navarre, Spain
-
Virgen de la Arrixaca University Hospital
RECRUITINGEl Palmar, Mur, Spain
-
Virgen del Rocio Hospital
RECRUITINGSeville, Sevilla, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?